Ophthalmic Pharmaceutical Drugs

SUMMARY

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million. The major therapeutic categories analyzed are Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 96 companies including many key and niche players worldwide such as Akorn, Inc., Alcon Eye Care, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Overview

• A Curtain Raiser
• Drugs Developed in the Recent Past
• What the Future Holds in Store?
• Where Does the Opportunity Lie?
• In the Shifting Demographics...
• Which Disease Segment Offers Abundant Opportunities for R&D Initiatives
• Leading Companies & Their Areas of Research Interest/Focus
• Business Opportunities in Ophthalmology: A Fact Sheet
• Impediments in Picking the Ripe & Low Hanging Opportunities
• Low Patient Compliance
• What's the Antidote to Low Patient Compliance?
• Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?
• An Unequivocal Discussion About Ocular Drug Design and Delivery
• Why Understanding of the Metabolic Activity of the Eye is Important?
• Pitfalls of Traditional Ocular Treatment
• Ophthalmic Drug Delivery: A Recapitulation of Facts
• Antidotes to Low Delivery of Ocular Drugs & High Side Effects
• Prodrug
• Soft Drugs (SDs)
• Soft Corticosteroids
• Drug Penetration Enhancers
• Chitosan Based Drugs & Drug Delivery Systems
• How Chitosan is used to Improve Ocular Drug Retention On the Eye's Surface?
• The Future of Ophthalmic Drug Delivery
• A Straight Talk About Ophthalmic Drug Delivery Technologies
• High Flying Expectations of Blistering Pace of Drug Development Grounded
• First Generation Advancements Made in Ocular Drugs
• Second Generation Advancements Made in Ocular Drugs
• Limiting Factors

2. Market Dynamics

• Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty...
• Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops
• Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs
• Aging Population & Environmental Factors Drive Growth
• Increase in Health Care Spending
• Opportunities Abound in the Developing Countries
• Innovative Products Lend Traction to Growth
• Reimbursements: "Under the Umbrella"
• Pricing Statistics On Select Ophthalmic Drugs in the United States for the Year 2006
• Price Changes for Select Ophthalmic Drugs in the Year 2005

3. An Overview of Ophthalmic Drugs

• Anti Viral Drugs
• Adenoviral Infections
• Herpes Simplex Virus
• Herpes Zoster (Varicella Zoster Disease)
• Corticosteroids
• Loteprednol
• Prednisolone
• Dexamethasone
• Fluorometholones
• Fluorometholone Alcohol
• Fluorometholone Acetate
• Rimexolone
• Clinical Efficacy of Steroids
• Topical Corticosteroid Drugs
• Tapering of Steroid Intake
• Non-Steroids Anti Inflammatory Drugs (NSAID)
• Use of Topical NSAIDs
• Topical & Systemic NSAIDs
• Ketorolac: A Potent NSAID
• Non-Steroidal Anti-Inflammatory Drugs
• Antibiotics
• Sodium Sulfacetamide
• Sulfisoxazole
• Bacitracin
• Bacitracin and Polymyxin B: A Powerful Duo
• Bacitracin, Polymyxin B and Neomycin: Three To Tango
• Trimethoprim with Polymyxin B
• Chloramphenicol
• Erythromycin
• Gentamicin and Tobramycin
• Fluoroquinolones
• Types of Fluoroquinolones
• Ciprofloxacin
• Gatifloxacin
• Levofloxacin
• Moxifloxacin
• Ofloxacin
• Topical Antibiotic Drugs
• Ophthalmic Antihistamines
• Azelastine
• Emedastine
• Epinastine
• Ketotifen
• Olopatadine
• Ophthalmic Mast-Cell Stabilizers
• Cromolyn
• Nedocromil Sodium
• Pemirolast
• Drugs to Treat Glaucoma
• Beta-Adrenergic Blockers or "Beta Blockers"
• Timolol
• Levobunolol
• Carteolol
• Metipranolol
• Betaxolol
• Alpha-Adrenergic Agonists
• Carbonic Anhydrase Inhibitors
• Acetazolamide
• Dorzolamide
• Acetazolamide & Dorzolamide: How Good Is the Combo?
• Miotics
• Prostaglandins
• Mydriatics & Cycloplegics
• Side Effects
• Over-The-Counter (OTC) Ophthalmic Preparations
• Artificial Tears
• Lubricating Ointments
• Mast Cell Stabilizers
• Antihistamines
• Phenylephrine
• Naphazoline
• Xylometazoline
• Astringents
• Over-The-Counter Ophthalmic Preparations
• A Directory Listing of Major Ophthalmic Pharmaceutical Drugs
• Formulary Anti- Glaucoma Drugs
• Non-Formulary Anti- Glaucoma Drugs
• Formulary Topical Anti-Glaucoma Drugs
• Formulary Ophthalmic Antiinfective/Corticosteroids Drugs
• Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs
• Formulary Ophthalmic Corticosteroid Drugs
• Non-Formulary Ophthalmic Corticosteroid Drugs
• Formulary Ophthalmic Topical Antibacterial Drugs
• Non-Formulary Ophthalmic Topical Antibacterial Drugs
• Formulary Ophthalmic Topical Antiviral Drugs
• Other Ophthalmic Formulary Drugs
• Other Ophthalmic Non-Formulary Drugs
• New Drugs In the Pipeline

4. Ophthalmic Disorders: A Freeze Frame

• The Human Eye: A Remarkable & Intriguing Organ of Sight
• The Outer Layer
• The Middle Layer
• The Inner Layer
• Common Ophthalmic Disorders: An Exposition
• Cataract
• Causes
• Types of Cataract
• Treatment Strategies
• How Widespread is the Disease?
• Glaucoma
• Who's At Risk?
• Types of Glaucoma
• Primary Open Angle Glaucoma (POAG)
• Acute Angle-Closure Glaucoma (AACG)
• Congenital Glaucoma
• Secondary Glaucoma
• Treatment Strategies
• Anti- Glaucoma Ophthalmic Drugs
• How Widespread is the Disease?
• Table 1: Prevalence of Glaucoma in the World: Year 1999 and 2006 A Comparison (In 000 Individuals) (includes corresponding Graph/Chart)
• Is Marijuana A Potential Cure?
• Age-Related Macular Degeneration (AMD)
• Types of AMD
• Dry AMD (Non-Neovascular)
• Wet AMD (Neovascular)
• Causes
• Treatment Strategies
• Nutrition & AMD
• Diabetic Retinopathy
• Treatment Strategies
• How Widespread is the Disease?
• Ocular Allergies
• Treatment Strategies
• Immunotherapy: A Popular Anti-Allergy Treatment Approach
• Ocular Inflammation: A Symptom of Ocular Allergies
• How Can Allergies Be Prevented?
• Conjunctivitis (Pink Eye)
• Types of Conjunctivitis
• Pathogenesis
• Treatment Strategies
• Keratitis
• Types of Keratitis
• Treatment Strategies
• Dry Eye
• Why Are Tears So Crucial for Normal Eye Health?
• What Causes Dry Eye?
• Treatment Strategies
• Refractive Errors
• Causes for Refractive error
• Treatment for Refractive Errors
• Cost of Treatment
• Factors contributing to the Difference in Surgery Costs

5. FDA Regulations and Approvals

• Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial
• Alimera Conducts Phase III Medidur Trial
• ISTA Pharmaceuticals Files NDA for Xibrom(tm) QD
• AzaSite Receives FDA Approval
• Alimera Sciences Receives FDA Approval
• Alcon Receives Approval for Vegamox(tm) Ophthalmic Solution in Japan
• Alcon Receives Marketing Approval for Patanol(r) in Japan
• Allergan Receives FDA Approval for Lumigan(r)
• Allergan's Ganfort(r) Receives Pan European License
• Pfizer Receives Approval from EC to Market Macugen(r)
• Akorn Gets Nod for Conducting Clinical Trial of AK-1015
• Genentech 's Lucentis Receives FDA Approval
• MacuSight Receives FDA Approval for IND Application of Sirolimus
• Sami Labs Receives Approval for Ocufors
• Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic Solutions
• Alcon's NEVANAC Receives FDA Approval
• Fougera Obtains Approval for MetroGel(r)
• Allergan's Alphagan P Receives FDA Approval
• Santen Obtains Approval for Manufacturing and Marketing PAPILOCK
• Alcon Receives FDA Approval for Adding Susceptible Pathogens to VIGAMOX
• BOL Receives FDA Approval for Ofloxacin
• Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin Ophthalmic Solution
• Vision Blue and DORC International Receives FDA Approval for Trypan Blue
• Pfizer Receives FDA Nod for Macugen(r)
• Bausch & Lomb Bags FDA Approval for its Zylet(tm)
• Alcon Receives Approval for Olopatadine (Patanol)
• Pharmacia Receives FDA Approval for Latanoprost Ophthalmic Solution
• US FDA Approves Allergan's New Acular LS 0.4% for Ocular Pain Reduction
• Allergan Obtains FDA Approval for Zymar

6. Product Innovations/Introductions

• Inspire Pharmaceuticals Rolls Out AzaSite(tm) for Ocular Infections
• Reckitt Benckiser Launches Two Eye Care Products
• Alcon Launches DUOTRAV for Glaucoma Treatment
• Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug
• Indoco Remedies to Launch Ophthalmic Drugs in America
• Akorn Launches Ophthalmic Drug Products
• AlphaRx Formulates the Ophthalmic Product, Binoxan(tm)
• Alimera Sciences Introduces Online Consumer Ordering Facility
• Fougera Adds Two Novel Products to its Ophthalmic Product Line
• Micro Vision Launches Anti-Glaucoma Drugs
• ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment in the US
• Falcon Unveils Trifluridine Ophthalmic Solution, 1%
• Alimera Sciences Unveils Soothe(tm) Emollient Eye Drops
• Novartis Introduces Zaditen in Japan
• Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%
• Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop
• Alcon Introduces Systane Lubricant Eye Drops
• Allergan Releases Restasis for Dry Eye Treatment
• Biosyntrx Launches BioTears
• Novartis to Introduce Pirenzepine Ophthalmic Gel

7. Recent Industry Activity

• Bausch & Lomb Acquires IOL Maker, Eyeonics
• Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution
• CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb
• Genaera Corporation Quits Evizon Clinical Trials
• Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer Program
• Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs
• Bausch & Lomb Acquire Soothe Products from Alimera
• Froptix, Acuity, eXegenics Merge to Form Opko Corporation
• Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel Antioxidants
• Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix(r)
• Inspire Pharmaceuticals Rolls Out AzaSite(tm) for Ocular Infections
• QLT Takes Over Forsight Newco II, Inc
• Phase IV Clinical Trials Of Macugen(r)
• Results Of Phase II Clinical Trials - Macugen(r)
• Macugen(r) Receives European Regulatory Approval
• Bausch & Lomb Purchases OTC Allergy Drugs of Alimera
• Phase II Trial of Acuity Pharmaceutical's Bevasiranib
• Advanced Refractive Technologies Acquires a Subsidiary of UTEK Corporation
• Sirion Therapeutics Acquires Sytera
• Teva Pharmaceuticals Acquires Ivax
• Alcon Enters into an Agreement with Amgen
• QLT Signs an Agreement with Retinagenix
• NicOx Enters into Licensing Agreement with Pfizer
• OccuLogix Signs Agreement to Acquire SOLX
• ISTA Receives License from Senju for Allergy Treatments
• Acuity Receives License for Nchlorotaurine
• Akorn and AVR Enter into Commercial Manufacturing & Supply Agreement
• Lantibio Signs Agreement with TRB Chemedica
• Argentis and Southern College of Optometry Enter into Agreement
• Bausch & Lomb Enters into Marketing Agreement with Novartis
• Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly
• Santen Pharmaceutical and CytoPathfinder Signs an Agreement
• Kalypsys Inks an Agreement with Alcon, Inc
• Combination RX Enters into a Collaboration Agreement with Fovea
• Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals
• Isotechnika Sells Eye Drug Rights to Lux Biosciences
• Alimera Sciences Collaborates With CYNACON
• Novartis Inks an In-Licensing Agreement with Otsuka
• Alimera Sciences Commences Phase III Trials for Medidur(tm)
• SurModics Acquires InnoRx
• Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group
• OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals
• Pfizer Acquires Angiosyn
• Bausch & Lomb Collaborates with PTC Therapeutics
• AMRI Enters into Research Collaboration with Alcon
• Bausch & Lomb Bags License from Cephalon
• PediaMed and Allergan Sign a Co-Promotion Agreement
• SurModics Bags Option to Acquire Exclusive Rights from Rutgers University
• Sankyo Co. and Santen Pharmaceutical Sign Agreement
• Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation
• Apotex Inks Marketing Agreement with Akorn
• Novartis Enters into an Agreement with Senju Pharmaceutical
• Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical
• Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution
• AMO Takes Over VISX
• Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer
• Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno
• Alimera Sciences Inks Co-promotion Agreement with VISTAKON Pharmaceuticals
• Akorn Inks a Purchase and Supply Agreement with FDC
• ISTA Pharmaceuticals Receives Marketing License From Senju Pharmaceuticals
• Pfizer Inc Acquires Pharmacia Corp
• Allergan Takes Over Oculex Pharmaceuticals
• Allergan Enters into an Agreement with Acadia

8. Focus on Select Global Players

• Akorn, Inc. (USA)
• Alcon Eye Care, Inc. (USA)
• Allergan, Inc. (USA)
• Alimera Sciences, Inc. (USA)
• Bausch & Lomb, Inc. (USA)
• Genvec, Inc. (USA)
• GlaxoSmithKline Plc (UK)
• Inspire Pharmaceuticals, Inc. (USA)
• ISTA Pharmaceuticals, Inc. (USA)
• Merck & Co., Inc. (USA)
• Novartis Ophthalmics (Canada)
• Opko Health, Inc (USA)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Pfizer Inc. (USA)
• QLT, Inc. (Canada)
• Santen Pharmaceutical Co. (Japan)
• Santen Inc. (USA)

9. Global Market Perspective

• Table 2: World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 3: World Long-term Projections for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 4: World 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 5: World Recent Past, Current and Future Analysis for Glaucoma by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 6: World Long-term Projections for Glaucoma by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 7: World 10-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 8: World Recent Past, Current and Future Analysis for Anti-allergy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-term Projections for Anti-Allergy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Anti-allergy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current and Future Analysis for Anti-infective by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Anti-Infective by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Anti-infective by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current and Future Analysis for Dry Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-term Projections for Dry Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Dry Eye by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current and Future Analysis for Anti-inflammation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for Anti-Inflammation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Anti-inflammation by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current and Future Analysis for Back of Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for Back of Eye by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for Back of Eye by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current and Future Analysis for Other Treatment Category by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for Other Treatment Category by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World 10-Year Perspective for Other Treatment Category by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Outlook
  • Emphasis on Greater Awareness About Ophthalmic Disorders
  • Growth Drivers In a Capsule
  • Impediments to Growth
  • Market Fact Sheet
  • Glaucoma Market: A Primer
  • Awareness Among Patients
  • High Costs
  • Treatment Patterns Adopted By Doctors
  • The All Consuming Issue of Compliance
  • Drug Brands & Their Patience Compliance Scores.
  • Market Share Statistics
  • The New Batting Order
  • Table 26: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (includes corresponding Graph/Chart)
  • Table 27: Top 10 Brands of Eye/Lens Care in the US: Breakdown of Dollar and Unit Sales Through Drug Stores, Supermarkets and Discount Stores For the Year Ended November 2007 (In US$ 000 and Thousand Units)
  • Table 28: Top 5 Eye Care Products in the US: Breakdown of Dollar Sales Through Food, Drug and Mass Market Channels for the Year Ended July 2007 (In US$ Million) (includes corresponding Graph/Chart)
  • Table 29: Age-Related Wet Macular Degeneration Market in the United States (2004-2006): Percentage Market Share Breakdown of Leading Players - QLT Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / Pfizer.
  • Table 30: Ocular Allergy Market in the United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (includes corresponding Graph/Chart)
  • Table 31: Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in the United States (2005 & 2006): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and ISTA Pharmaceuticals (includes corresponding Graph/Chart)
  • Table 32: Age-Related Macular Degeneration Market in the United States (2006, 2009 & 2012): Dollar Sales of Major Branded Drugs - Visudyne, Macugen, and Lucentis (In US$ Million) (includes corresponding Graph/Chart)
  • Age-Related Macular Degeneration Market in the United States (2006) - New Brands Expected to hit the Market
  • Update On Drugs & Their Manufacturers in the US
  • Patent Expirations of Key Ophthalmic Product Brands in the United States
  • Major Anti-Glaucoma Drugs Available in the United States: Year 2006
  • Major Drugs Available in the United States for the Treatment of AMD: Year 2005
  • Drugs in the Pipeline for the Treatment of AMD in the United States: Year 2005
  • Major Drugs Available in the United States for the Control of Dry Eye: Year 2005
  • US Market for Dry Eye: Drugs in the Pipeline Year 2005
  • Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005
  • Major Drugs Available in the United States for the Treatment of Ocular Allergies: Year 2005
  • US Market for Ocular Allergies: Drugs in the Pipeline: Year 2005
  • Statistical Findings On Ophthalmic Diseases in the United States
  • Table 33: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet AMD & Intermediate Dry AMD by Age Group for the Year 2005 (includes corresponding Graph/Chart)
  • Table 34: Prevalence of Age-Related Wet Macular Degeneration in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 35: Number of Individuals Treated for Wet AMD in the United States (In Thousands) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)
  • Table 36: Prevalence of Ocular Hypertension (OHT) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 37: Prevalence of Primary Open Angle Glaucoma (POAG) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 38: Prevalence of Normal Tension Glaucoma (NTG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)
  • Table 39: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)
  • Table 40: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart)
  • Table 41: Number of Individuals Treated for Glaucoma in the United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (OHT), Primary Open Angle Glaucoma (POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma (PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) (includes corresponding Graph/Chart)
  • Table 42: Prevalence of Ocular Allergy in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 43: Number of Individuals Treated for Ocular Allergy in the United States (In Million) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)
  • Table 44: Prevalence of Cataract in the United States: Percentage Breakdown by Age Group for the Year 2005 (includes corresponding Graph/Chart)
  • Table 45: Prevalence of Cataract in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 46: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory Drugs) in the United States for the Years 2006, 2009 & 2012 ((In Millions) (includes corresponding Graph/Chart)
  • Table 47: Prevalence of Dry Eye in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart)
  • Table 48: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart)
  • FDA Approvals
  • Product Launches
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 49: US Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 50: US Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti- inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 51: US 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Outlook
  • Lack of Awareness: A Key Issue
  • Key Players
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 52: Canadian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 53: Canadian Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti- inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 54: Canadian 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Outlook
  • Growth Drivers
  • Market Data Statistics
  • Leading Ophthalmic Pharmaceutical Brands In the Market
  • Table 55: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area - Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (includes corresponding Graph/Chart)
  • Product Launches
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 56: Japanese Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 57: Japanese Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti- inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 58: Japanese 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Outlook
  • A Market Primer
  • Drug Reimbursement in Europe
  • Key Player
• B. Market Analytics
  • Table 59: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)
  • Table 62: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 63: European Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 64: European 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Outlook
  • Strategic Corporate Development
• B. Market Analytics
  • Table 65: French Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 66: French Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 67: French 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4b. Germany

• Market Analysis
• Table 68: German Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 69: German Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 70: German 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4c. The United Kingdom

• A. Market Analysis
  • Outlook
  • Key Player
• B. Market Analytics
  • Table 71: UK Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 72: UK Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 73: UK 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4d. Italy

• Market Analysis
• Table 74: Italian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 75: Italian Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 76: Italian 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4e. Spain

• A. Market Analysis
  • Outlook
  • How & Why the Health Insurance System in Spain is Conducive?
  • Pharmaceutical Reimbursement Reforms in Spain (1996-2002)
• B. Market Analytics
  • Table 77: Spanish Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 78: Spanish Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 79: Spanish 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

4f. Rest of Europe

• A. Market Analysis
  • Outlook
  • Product Launch
  • Strategic Corporate Development
• B. Market Analytics
  • Table 80: Rest of Europe Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti- infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 81: Rest of Europe Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 82: Rest of Europe 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Outlook
  • Product Launch
  • Strategic Corporate development
• B. Market Analytics
  • Table 83: Asia-Pacific Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 84: Asia-Pacific Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 85: Asia-Pacific 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

6. Latin America

• Market Analysis
• Table 86: Latin American Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 87: Latin America Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 88: Latin American 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti- allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)

7. Rest of World

• A. Market Analysis
  • Outlook
  • Strategic Corporate Development
• B. Market Analytics
  • Table 89: Rest of World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 90: Rest of World Long-term Projections for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 91: Rest of World 10-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2003, 2008 and 2012 (includes corresponding Graph/Chart)